Mark Rothera, President and CEO of Silence Therapeutics PLC talks to Proactive about their new deal with one of China’s biggest drug developers in a deal that could be worth US$1.3bn in milestone payments.
As part of the deal the firm will receive US$16mln straight away as part of the collaboration agreement with Hansoh Pharma. The two aim to create new treatments using Silence’s mRNAi GOLD platform, which has been specially created to find liver disease treatments.
Under the terms of the transaction, Silence will gain exclusive rights to two resultant drug candidates everywhere except in greater China.